Kura Oncology, Inc. Q3 2026 Earnings Recap

Kura reported continued commercial growth for COMZIFTI and progress on darlafarnib, with the stock up 2.1% after earnings—a roughly flat reaction. The update included positive launch metrics, but the transcript provided no new full-year revenue guidance or complete clinical data to assess the broader outlook.

Key Takeaways

• COMZIFTI third-quarter net product revenue was $13.9 million, up 53% sequentially; new patient starts rose about 30% to approximately 150.
• Total prescriptions increased 65% to more than 2,400, and 170 accounts had prescribed COMZIFTI, up 40% quarter over quarter. Kura said it maintained a majority share of menin-inhibitor new patient starts in the approved setting.
• Kura said it aligned with FDA on a single-arm monotherapy registrational study of darlafarnib in HRAS-mutant salivary gland cancer.
• Eight Ziftomenib abstracts are planned for ASH, including first clinical data on combinations with FLT3 inhibitors; the call excerpt did not provide the data or resulting development decisions.
• Management cited a strategic financing agreement with OrbiMed as providing flexibility to fund key milestones, but gave no specific funding outlook figures in the excerpt.